The Melbourne Consensus Statement on the early detection of prostate cancer

BJU International

Volumn 113, Issue 2, 2014, Pages 186-188

  Murphy, Declan G ^a,b,c   Ahlering, Thomas ^d   Catalona, William J ^e   Crowe, Helen ^b,c   Crowe, Jane ^c   Clarke, Noel ^j   Cooperberg, Matthew ^f   Gillatt, David ^k   Gleave, Martin ^l   Loeb, Stacy ^g   Roobol, Monique ^m   Sartor, Oliver ^h   Pickles, Tom ^l   Wootten, Addie ^c   Walsh, Patrick C ⁱ   Costello, Anthony J ^b,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c EPWORTH HEALTHCARE   (Australia)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g NEW YORK UNIVERSITY   (United States)

^h TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY   (United States)

^j UNIVERSITY OF MANCHESTER   (United Kingdom)

^k UNIVERSITY OF BRISTOL   (United Kingdom)

^l UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^m ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

guideline; prostate cancer; PSA testing; risk stratification; screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; AUSTRALIA; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; DECISION MAKING; EARLY DIAGNOSIS; FOLLOW UP; HUMAN; LIFE EXPECTANCY; METASTASIS; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER;

GUIDELINE; PROSTATE CANCER; PSA TESTING; RISK STRATIFICATION; SCREENING;

AGED; AUSTRALIA; CONSENSUS; DECISION MAKING; DIGITAL RECTAL EXAMINATION; EARLY DETECTION OF CANCER; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84892497571     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12556     Document Type: Article

References (21)

1. Moyer VA, U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157: 120-134
2. Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA guideline. J Urol 2013; 190: 419-426
3. NCCN. Prostate cancer early detection guidelines 2012 v.2. Available at: http://www.nccn.org. Accessed November 2013
4. Heidenreich A, Abrahamsson PA, Artibani W, et al. Early detection of prostate cancer: European association of urology recommendation. Eur Urol 2013; 64: 347-354
5. Schroder FH, Hugosson J, Carlsson S, et al. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2012; 62: 745-752
6. Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366: 981-990
7. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010; 11: 725-732
8. Bul M, Zhu X, Valdagni R, et al. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol 2013; 63: 597-603
9. Bangma CH, Bul M, Roobol M,. The Prostate cancer Research International: active surveillance study. Curr Opin Urol 2012; 22: 216-221
10. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A,. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28: 126-131
11. European Randomized Study of Screening for Prostate Cancer. ERSPC risk calculator, 2013. Available at: http://www.prostatecancer-riskcalculator.com. Accessed November 2013
12. UT Health Science Center. Prostate cancer prevention trial risk calculator, 2013. Available at: http://deb.uthscsa.edu/URORiskCalc/Pages/ uroriskcalc.jsp. Accessed November 2013
13. Sunnybrook Health Sciences Centre. Prostate cancer risk calculator, 2013. Available at: http://www.prostaterisk.ca. Accessed November 2013
14. Loeb S,. Use of baseline prostate-specific antigen measurements to personalize prostate cancer screening. Eur Urol 2012; 61: 875-876
15. Lilja H, Cronin AM, Dahlin A, et al. Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer 2011; 117: 1210-1219
16. Vickers AJ, Ulmert D, Sjoberg DD, et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ 2013; 346: f2023
17. McKenzie P, Delahunt B, deVoss K, Ross B, Tran H, Sikaris K,. Prostate specific antigen testing for the diagnosis of prostate cancer. Pathology 2011; 43: 403
18. Evans SM, Millar JL, Davis ID, et al. Patterns of care for men diagnosed with prostate cancer in Victoria from 2008 to 2011. Med J Aust 2013; 198: 540-545
19. Scosyrev E, Wu G, Mohile S, Messing EM,. Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: analysis of trends over time. Cancer 2012; 118: 5768-5776
20. Smith JA Jr,. What would you do, doctor? J Urol 2009; 182: 421-422
21. Andros EA, Danesghari F, Crawford ED,. Neoadjuvant hormonal therapy in stage C adenocarcinoma of the prostate. Clin Invest Med 1993; 16: 510-515